SurveyCXCR3 ligands in disease and therapy
Section snippets
An introduction to chemokines
Originally discovered to be chemotactic cytokines leading the way for leukocytes in health and inflammation, the chemokines have now made a name for themselves as pleiotropic molecules involved in a range of physiological as well as pathological processes [1], [2]. Most of their effects are established by signaling through a set of chemokine receptors, typically G protein-coupled receptors (GPCR). Notably, chemokine ligand/receptor binding is both a promiscuous and a redundant interaction,
The CXCR3 receptor
The CXCR3 receptor is a seven-transmembrane GPCR, classified as a CXC-type receptor based on the structure of its chemokine ligands. This receptor was indeed originally cloned and characterized as an activated T lymphocyte-expressed GPCR selective for ELR-negative CXC chemokines CXCL9 and CXCL10 [13]. In contrast to other chemokine receptors, the human CXCR3 gene was allocated to the X chromosome, in the q13 region [23]. In culture, the percentage of CXCR3-positive T lymphocytes has been shown
CXCR3 ligands in disease
Given their pleiotropic nature, CXCR3 ligands play their part in a myriad of diseases. Involvement of all CXCR3 ligands has been observed in various angiogenesis-related pathologies as well as immunological disorders, the latter being mostly related to autoimmunity or infection [45], [46]. Here we discuss a varied and extensive, yet not exhaustive, repertoire of diseases having been associated with CXCL4, CXCL4L1, CXCL9, CXCL10 or CXCL11. The CXCR3 ligands are indeed characterized by their
CXCR3 ligands in therapy
A great range of pathologies, mostly characterized by inflammation or vascular effects, have clearly been associated with changes in the expression levels of CXCR3 and CXCR3-binding chemokines (summarized in Table 2). More importantly, often the expression of these chemokine ligands and receptor correlates with pathogenesis, disease progression and prognosis or, under particular conditions, could reflect a failing compensation mechanism. Insight into CXCR3 biology has consequently inspired the
Summary
CXCL4, CXCL4L1, CXCL9, CXCL10 and CXCL11 all bind, with varying affinity, to different splice variants of the CXCR3 receptor and are therefore collectively referred to as the CXCR3 ligands. Their pleiotropic character, regulating both leukocyte migration and angiogenesis, implicates these chemokines in a broad spectrum of diseases and their pathogenesis. Consequently, the CXCR3 ligands have attracted attention as new therapeutic targets. However, the field is still lacking fundamental
Acknowledgements
The authors would like to thank for granted support by the Fund for Scientific Research of Flanders (FWO-Vlaanderen project G.0764.14 and G.0773.13), the Interuniversity Attraction Poles Programme initiated by the Belgian Science Policy Office (I.A.P. project P7/40) and the Concerted Research Actions of the Regional Government of Flanders (GOA13/014).
Katrien Van Raemdonck graduated as master in biomedical sciences in 2009 and obtained a PhD in biomedical sciences in 2014, under the promotership of Prof. Dr. Sofie Struyf and Prof. Dr. Jo Van Damme at the Rega Institute, University of Leuven, Belgium. Her research interests are primarily focused on the role of chemokines in angiogenesis and cancer.
References (299)
- et al.
Chemokines: a new classification system and their role in immunity
Immunity
(2000) - et al.
The functional role of the ELR motif in CXC chemokine-mediated angiogenesis
J Biol Chem
(1995) - et al.
Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3
Blood
(2011) - et al.
The CXC-chemokine platelet factor 4 promotes monocyte survival and induces monocyte differentiation into macrophages
Blood
(2000) - et al.
CXCR3 in T cell function
Exp Cell Res
(2011) - et al.
A novel transcription factor, T-bet, directs Th1 lineage commitment
Cell
(2000) - et al.
CXCR3 chemokine receptor distribution in normal and inflamed tissues: expression on activated lymphocytes, endothelial cells, and dendritic cells
Lab Invest
(2001) - et al.
a double-edged sword in tumor progression and angiogenesis
Biochim Biophys Acta
(2013) - et al.
Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function
J Biol Chem
(2004) - et al.
Role of CXCR3 carboxyl terminus and third intracellular loop in receptor-mediated migration, adhesion and internalization in response to CXCL11
Blood
(2006)
TLR ligands and cytokines induce CXCR3 ligands in endothelial cells: enhanced CXCL9 in autoimmune arthritis
Lab Invest
Alternative C-Terminal Helix Orientation Alters Chemokine Function: structure of the anti-angiogenic chemokine, CXCL4L1
J Biol Chem
PF-4/CXCL4 and CXCL4L1 exhibit distinct subcellular localization and a differentially regulated mechanism of secretion
Blood
The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancer
Cytokine Growth Factor Rev
The role of CXC chemokines and their receptors in cancer
Cancer Lett
CXCL4L1-fibstatin cooperation inhibits tumor angiogenesis, lymphangiogenesis and metastasis
Microvasc Res
The expression and role of CXC chemokines in colorectal cancer
Cytokine Growth Factor Rev
Cellular characteristics of neuroblastoma cells: regulation by the ELR−-CXC chemokine CXCL10 and expression of a CXCR3-like receptor
Cytokine
The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines
Immunol Lett
Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells
J Biol Chem
The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia
Blood
Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia
Blood
Protumoral role of monocytes in human B-cell precursor acute lymphoblastic leukemia: involvement of the chemokine CXCL10
Blood
Evaluation of circulating concentrations of CXCL1 (Gro-alpha), CXCL10 (IP-10) and CXCL12 (SDF-1) in ALL patients prior and post bone marrow transplantation
Pathol Res Pract
Translocation 4–11 in acute lymphoblastic-leukemia – clinical characteristics and prognostic-significance
Blood
Platelet factor-4 is an indicator of blood count recovery in acute myeloid leukemia patients in complete remission
Mol Cell Proteomics
Tyrosine kinase chromosomal translocations mediate distinct and overlapping gene regulation events
BMC Cancer
CXCR3-binding chemokines in multiple myeloma
Cancer Lett
4q loss is potentially an important genetic event in MM tumorigenesis: identification of a tumor suppressor gene regulated by promoter methylation at 4q13.3, platelet factor 4
Blood
Platelet factor 4 and other CXC chemokines support the survival of normal hematopoietic cells and reduce the chemosensitivity of cells to cytotoxic agents
Blood
Chemokine (C–X–C motif) ligand (CXCL)10 in autoimmune diseases
Autoimmun Rev
CXCR3 and CCR5 ligands in rheumatoid arthritis synovium
Clin Immunol
The chemokine system – a major regulator of angiogenesis in health and disease
APMIS
CXCR3 ligands: redundant, collaborative and antagonistic functions
Immunol Cell Biol
New nomenclature for atypical chemokine receptors
Nat Immunol
CXC chemokines in angiogenesis
J Leukoc Biol
Angiogenic and antiangiogenic chemokines
Chem Immunol Allergy
The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity
J Immunol
Structure and functional expression of a human interleukin-8 receptor
Science
The role of CXCR7 on the adhesion, proliferation and angiogenesis of endothelial progenitor cells
J Cell Mol Med
An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4
J Exp Med
Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3
J Exp Med
Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes
J Exp Med
Identification and partial characterization of a variant of human CXCR3 generated by posttranscriptional exon skipping
J Immunol
Regulation of protein function by glycosaminoglycans – as exemplified by chemokines
Annu Rev Biochem
The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation
J Exp Med
Glycosaminoglycan and chemokine/growth factor interactions
Handb Exp Pharmacol
Serglycin-binding proteins in activated macrophages and platelets
J Leukoc Biol
Platelet factor 4/CXCL4 induces phagocytosis and the generation of reactive oxygen metabolites in mononuclear phagocytes independently of Gi protein activation or intracellular calcium transients
J Immunol
A chondroitin sulfate proteoglycan on human neutrophils specifically binds platelet factor 4 and is involved in cell activation
J Immunol
Cited by (248)
Cell type- and region-specific translatomes in an MPTP mouse model of Parkinson's disease
2023, Neurobiology of DiseaseEGFR pathway targeting drugs in head and neck cancer in the era of immunotherapy
2023, Biochimica et Biophysica Acta - Reviews on Cancer
Katrien Van Raemdonck graduated as master in biomedical sciences in 2009 and obtained a PhD in biomedical sciences in 2014, under the promotership of Prof. Dr. Sofie Struyf and Prof. Dr. Jo Van Damme at the Rega Institute, University of Leuven, Belgium. Her research interests are primarily focused on the role of chemokines in angiogenesis and cancer.
Philippe E. Van den Steen graduated as bio-engineer in 1997 at the University of Leuven in Belgium. He obtained his PhD degree in medical sciences in 2001 at the Laboratory of Immunobiology (Rega Institute, KU Leuven), with the glycosylation and substrates of gelatinase B/matrix metalloproteinase-9 as research topic. Subsequently, he started a novel malaria research line at the Rega Institute and performed a research stay at the London School of Hygiene and Tropical Medicine. Presently, he is holding a research professorship at the Rega Institute and his research is focusing on the immunobiology of malaria complications.
Sandra Liekens graduated as bio-engineer in 1994 at the University of Leuven, Belgium. She obtained her PhD degree (2000) in applied biological sciences at the Rega Institute (Laboratory of Virology and Chemotherapy, University of Leuven, Belgium) on the inhibition of vascular tumor growth by anti-angiogenic and apoptosis-inducing agents. She is holding a position of professor at the Rega Institute. Her research is currently focused on understanding the interplay between viral and cellular factors involved in angiogenesis and the characterization of anti-angiogenic and vascular-targeting agents.
Jo Van Damme (1950, bio-engineer, PhD, University of Ghent, Belgium) is professor at the Medical Faculty of the University of Leuven, Belgium, and Head of the Laboratory of Molecular Immunology, at the Rega Institute for Medical Research. He was president of the European Cytokine Society (2001–2007). He has done pioneer work in cytokine research and was involved in the identification of several human interleukins and chemokines. His current research is dealing with the role of chemoattractants and post-translationally modified forms thereof in infection, inflammation and cancer.
Sofie Struyf graduated as bio-engineer in 1996 at the University of Leuven, Belgium. She obtained her PhD degree (2002) in applied biological sciences at the Rega Institute (Laboratory of Molecular Immunology, University of Leuven, Belgium) on post-translational modifications of chemokines. She is holding a position of professor at the Rega Institute. Her research is currently focused on the role of chemokines in angiogenesis and cancer.